PFE Pfizer (PFE) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000078003
Cluster · 3 insidersC-suite buying · 1Congress · 1
Funds added, last quarter
1,323
13F, latest reported quarter
What the filings say about PFE
Insiders, 180 days
+$2.8M net bought
3 buyers · 1 seller · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 2 sold
Latest: sale, 2026-03-13
Pfizer insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, PFIZER INC insiders bought a net $2.8M of stock across 87 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 8.9% of the 429,173 shares held after it.
- 2 other insiders bought within 30 days.
- 1,323 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman & CEO BOURLA ALBERT bought about $1.0M of PFE on Aug 12, 2026, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 1,323 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 37,632 shares held after it.
- 2 other insiders bought within 30 days.
- 1,323 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Buckley Mortimer J bought about $960.4K of PFE on Aug 5, 2026, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 1,323 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Feb 13, 2025.
- The trade is 58.6% of the 66,938 shares held after it.
- 2 other insiders bought within 30 days.
- 1,323 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BLAYLOCK RONALD E bought about $998.8K of PFE on Aug 5, 2026, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 1,323 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Jun 9, 2026.
- The trade is 11.5% of the 28,611 shares held after it.
- No other insider sold within 30 days.
- 1,323 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & Controller DAMICO JENNIFER B. sold about $83.3K of PFE on Aug 5, 2026, the largest insider sale at the company since 2024; 1,323 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Mar 4, 2025.
- The trade is 6.4% of the 31,397 shares held after it.
- No other insider sold within 30 days.
- 1,323 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & Controller DAMICO JENNIFER B. sold about $51.4K of PFE on Jun 9, 2026, the largest insider sale at the company since 2025; 1,323 funds added in the latest 13F quarter.87 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$2.8M over 180 days
+$2.9M over 90 days
more than 93% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
1,323 funds bought in last quarter
more than 99% of Pharma & Biotech
Revenue
-1.6% year over year
below 59% of Pharma & Biotech
Margin
12.4% net margin
more than 82% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
2.6% of the float short (float per yahoo 2026-10-26) · 4.4 days to cover · settled 2026-09-30
below 62% of Pharma & Biotech
The situation: each line is one rule over one dataset
4 clinical trials were terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch PFE
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+29.2%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PFE: institutional holders (13F)
13F holdings, latest reported quarter
529,670,433 sh
$12.8B
372,149,852 sh
$9.0B
307,090,897 sh
$7.4B
135,275,782 sh
$3.2B
119,235,030 sh
$2.9B
Congress trades in PFE
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-03-13 · disclosed 25 days later
$1,001 - $15,000
Bought 2026-02-10 · disclosed 27 days later
$1,001 - $15,000
Sold 2025-12-31 · disclosed 23 days later
$100,001 - $250,000
Sold 2025-12-19 · disclosed 24 days later
$1,001 - $15,000
Bought 2025-11-18 · disclosed 27 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PFE planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
PFE mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Roundhill GLP-1 & Weight Loss ETF
$3.5M position · as of 2026-06-30
6.4%
First Trust Morningstar Dividend Leaders Index Fund
$430.6M position · as of 2026-06-30
5.9%
Huber Select Large Cap Value Fund
$24.9M position · as of 2026-07-31
5.0%
Franklin U.S. Dividend Booster Index ETF
$3.4M position · as of 2026-06-30
4.6%
VanEck Pharmaceutical ETF
$39.6M position · as of 2026-06-30
4.5%
Invesco Pharmaceuticals ETF
$21.2M position · as of 2026-07-31
4.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
1007 registered trials, 239 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
310
Phase 1
38 active
108
Phase 2
24 active
177
Phase 3
84 active
35
Phase 4
10 active
327
Not applicable
65 active
50
Multi-phase
18 active
What changed recently
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who H
2026-10-24 · Completion moved 2026-10-19 → 2026-11-12
Phase 2
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who H
2026-10-24 · Recruiting → Active Not Recruiting
Phase 2
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent
2026-10-24 · Completion moved 2028-08-19 → 2030-02-26
Phase 3
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failur
2026-10-24 · Completion moved 2027-11-16 → 2028-05-08
Phase 2
A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Childr
2026-10-24 · Completion moved 2027-05-14 → 2027-06-10
Phase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tole
2026-10-23 · Active Not Recruiting → Completed
Phase 1
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Pfizer Inc. Pac
Cycle 2026 · $1,258K spent
$1.3M
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Bourla
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$27.6M
$33.7M
$9.6M
-14%
+87%
2024
$24.6M
$38.5M
$8.5M
-14%
+51%
2023
$21.6M
-$62.1M
$6.3M
-12%
+43%
2022
$33.0M
$5.7M
$14.8M
+49%
+33%
2021
$24.4M
$115.2M
$9.3M
+67%
+23%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $2.8M bought by insiders over 180 days, 1,323 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
PFE financials
Revenue growth
-1.6%
XBRL, annual
Net margin
12.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$63.7B
four quarters, 2025-06-30 to 2026-06-28
Revenue, TTM PFE
| FY Dec 2025 | $62.6B |
| FY Dec 2024 | $63.6B |
| FY Dec 2023 | $59.6B |
| FY Dec 2022 | $101.2B |
| FY Dec 2021 | $81.3B |
| Jun 2026 | $15.0B |
| Mar 2026 | $14.5B |
| Dec 2025 | $17.6B |
| Sep 2025 | $16.7B |
| Jun 2025 | $14.7B |
| Mar 2025 | $13.7B |
| Dec 2024 | $17.8B |
| Sep 2024 | $17.7B |
At each fiscal year end
Single quarter
Net margin, TTM
+6.8%
net income over revenue, 2025-06-30 to 2026-06-28
Net margin, TTM PFE
| FY Dec 2025 | +12.4% |
| FY Dec 2024 | +12.6% |
| FY Dec 2023 | +3.6% |
| FY Dec 2022 | +31.0% |
| FY Dec 2021 | +27.0% |
| Jun 2026 | -1.6% |
| Mar 2026 | +18.6% |
| Dec 2025 | -9.4% |
| Sep 2025 | +21.3% |
| Jun 2025 | +19.9% |
| Mar 2025 | +21.6% |
| Dec 2024 | +2.3% |
| Sep 2024 | +25.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$11.0B
operating cash flow minus capex, 2025-06-30 to 2026-06-28
Free cash flow, TTM PFE
| FY Dec 2025 | $9.1B |
| FY Dec 2024 | $9.8B |
| FY Dec 2023 | $4.8B |
| FY Dec 2022 | $26.0B |
| FY Dec 2021 | $29.9B |
| Jun 2026 | $302.0M |
| Mar 2026 | $2.2B |
| Dec 2025 | $4.5B |
| Sep 2025 | $4.0B |
| Jun 2025 | -$1.2B |
| Mar 2025 | $1.8B |
| Dec 2024 | $5.8B |
| Sep 2024 | $6.1B |
At each fiscal year end
Single quarter
Debt to equity
0.74x
long-term 2026-06-28 plus current 2026-06-28; equity 2026-06-28
Debt to equity PFE
| FY Dec 2025 | 0.75x |
| FY Dec 2024 | 0.73x |
| FY Dec 2023 | 0.81x |
| FY Dec 2022 | 0.37x |
| FY Dec 2021 | 0.50x |
| Jun 2026 | 0.74x |
| Mar 2026 | 0.72x |
| Dec 2025 | 0.75x |
| Sep 2025 | 0.66x |
| Jun 2025 | 0.70x |
| Mar 2025 | 0.69x |
| Dec 2024 | 0.73x |
| Sep 2024 | 0.73x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.21x
TTM operating cash flow over long-term 2026-06-28 plus current 2026-06-28
Cash flow to debt PFE
| FY Dec 2025 | 0.18x |
| FY Dec 2024 | 0.20x |
| FY Dec 2023 | 0.12x |
| FY Dec 2022 | 0.82x |
| FY Dec 2021 | 0.85x |
| Jun 2026 | 0.21x |
| Mar 2026 | 0.19x |
| Dec 2025 | 0.18x |
| Sep 2025 | 0.21x |
| Jun 2025 | 0.25x |
| Mar 2025 | 0.23x |
| Dec 2024 | 0.20x |
| Sep 2024 | 0.17x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+5.0%
TTM net income over average of 2025-06-29 and 2026-06-28
Return on equity PFE
| FY Dec 2025 | +8.9% |
| FY Dec 2024 | +9.1% |
| FY Dec 2023 | +2.3% |
| FY Dec 2022 | +36.3% |
| FY Dec 2021 | +31.3% |
| Jun 2026 | +5.0% |
| Mar 2026 | +8.3% |
| Dec 2025 | +8.9% |
| Sep 2025 | +10.6% |
| Jun 2025 | +12.2% |
| Mar 2025 | +8.6% |
| Dec 2024 | +9.1% |
| Sep 2024 | +4.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+2.1%
TTM net income over average of 2025-06-29 and 2026-06-28
Return on assets PFE
| FY Dec 2025 | +3.7% |
| FY Dec 2024 | +3.7% |
| FY Dec 2023 | +1.0% |
| FY Dec 2022 | +16.6% |
| FY Dec 2021 | +13.1% |
| Jun 2026 | +2.1% |
| Mar 2026 | +3.6% |
| Dec 2025 | +3.7% |
| Sep 2025 | +4.6% |
| Jun 2025 | +5.1% |
| Mar 2025 | +3.7% |
| Dec 2024 | +3.7% |
| Sep 2024 | +2.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital PFE
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed PFE
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
39.20x
close 2026-10-26 over four quarters of diluted EPS, 2025-06-30 to 2026-06-28
P/E, trailing PFE
| FY Dec 2025 | 18.31x |
| FY Dec 2024 | 18.82x |
| FY Dec 2023 | 77.81x |
| FY Dec 2022 | 9.35x |
| FY Dec 2021 | 15.38x |
| Jun 2026 | 31.96x |
| Mar 2026 | 20.64x |
| Dec 2025 | 18.31x |
| Sep 2025 | 13.81x |
| Jun 2025 | 12.87x |
| Mar 2025 | 18.27x |
| Dec 2024 | 18.82x |
| Sep 2024 | 38.79x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$232.0B
market value at close 2026-10-26 on 2026-07-29 shares, plus long-term 2026-06-28 plus current 2026-06-28, minus cash 2026-06-28
Enterprise value PFE
| FY Dec 2025 | $205.2B |
| FY Dec 2024 | $213.7B |
| FY Dec 2023 | $231.6B |
| FY Dec 2022 | $323.0B |
| FY Dec 2021 | $367.9B |
| Jun 2026 | $200.7B |
| Mar 2026 | $216.5B |
| Dec 2025 | $205.2B |
| Sep 2025 | $195.5B |
| Jun 2025 | $197.7B |
| Mar 2025 | $203.6B |
| Dec 2024 | $213.7B |
| Sep 2024 | $231.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+6.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield PFE
| FY Dec 2025 | +6.4% |
| FY Dec 2024 | +6.5% |
| FY Dec 2023 | +2.9% |
| FY Dec 2022 | +9.1% |
| FY Dec 2021 | +9.0% |
| Jun 2026 | +7.9% |
| Mar 2026 | +6.2% |
| Dec 2025 | +6.4% |
| Sep 2025 | +7.7% |
| Jun 2025 | +9.0% |
| Mar 2025 | +7.9% |
| Dec 2024 | +6.5% |
| Sep 2024 | +5.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -60%, PEG needs growth
PEG, trailing PFE
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.07x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 0.22x |
| FY Dec 2021 | 0.11x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 0.11x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | 0.07x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $62.6B | $63.6B | $59.6B | $101.2B |
| Net income | $7.8B | $8.0B | $2.1B | $31.4B |
| EPS (diluted) | 1.36 | 1.41 | 0.37 | 5.47 |
| Operating cash flow | $11.7B | $12.7B | $8.7B | $29.3B |
| Cash | $1.1B | $1.0B | $2.9B | $416.0M |
| Long-term debt | $61.6B | $57.4B | $61.5B | $32.9B |
| Buybacks | n/a | $0 | $0 | $2.0B |
SEC XBRL, fiscal years, as known on 2026-10-28
PFE Stock Sonar score 6/7 axes
Find similar shapesComparePFE ranks highest on insider conviction (91st percentile) and profitability (83rd), and lowest on growth (28th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PFE filings, in plain words
Are Pfizer insiders buying or selling PFE?
In the 180 days to 2026-10-28, Pfizer insiders were net buyers, a net $2.8M: $3.0M of purchases and $134.7K of sales reported on Form 4, by 3 buyers and 1 seller.
Have members of Congress traded PFE?
Yes. In the year to 2026-10-28, 1 House member disclosed buying PFE and 2 House members disclosed selling it; the latest on record is a sale by Gilbert Cisneros dated 2026-03-13.
Read the full summary
In the 180 days to 2026-10-28, Pfizer insiders were net buyers of PFE, a net $2.8M across purchases and sales reported on Form 4 by 3 buyers and 1 seller. Purchases outweighed sales more than tenfold by value. 3 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. In the year to 2026-10-28, 1 member of Congress disclosed buying PFE and 2 members disclosed selling it; the latest on record is a sale by Gilbert Cisneros dated 2026-03-13. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
